Trial Search Results

An Observational Study of Fungal Biomarkers (MK-0000-089)

The purpose of this study is to evaluate the relationship between fungal biomarker levels during anti-fungal therapy and the success of treatment for fungal infection. The primary hypothesis is that over the initial two weeks of anti-fungal therapy, fungal biomarkers from participants with invasive aspergillosis (IA) will be lower for those with a successful clinical outcome compared to those with a failed clinical outcome.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Merck Sharp & Dohme Corp.

Stanford Investigator(s):


  • Other: No Intervention


Inclusion Criteria:

   - Is 16 years of age or older

   - Female is either post-menopausal, surgically sterilized, willing to use 2 adequate
   methods of birth control, or agrees to abstain from heterosexual activity throughout
   the study

   - Female of child bearing potential must have a negative pregnancy test

   - Male is surgically sterilized, agrees to use an adequate method of contraception, or
   agrees to abstain from heterosexual activity for the duration of the study

   - Has possible, probable, or confirmed invasive aspergillosis (IA)

   - Has had a computed tomography (CT) or magnetic resonance imaging (MRI) scan 72 hours
   prior to initiation of anti-fungal therapy

Exclusion Criteria:

   - Has had hemodialysis using cellulose membrane within 2 weeks of study start

Ages Eligible for Study

16 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
Not Recruiting